% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Bhardwaj:147183,
author = {M. Bhardwaj$^*$ and A. Gies$^*$ and K. Weigl$^*$ and K.
Tikk and A. Benner$^*$ and P. Schrotz-King$^*$ and C. H.
Borchers and H. Brenner$^*$},
title = {{E}valuation and {V}alidation of {P}lasma {P}roteins
{U}sing {T}wo {D}ifferent {P}rotein {D}etection {M}ethods
for {E}arly {D}etection of {C}olorectal {C}ancer.},
journal = {Cancers},
volume = {11},
number = {10},
issn = {2072-6694},
address = {Basel},
publisher = {MDPI},
reportid = {DKFZ-2019-02319},
pages = {1426},
year = {2019},
abstract = {Plasma protein biomarkers could be an efficient alternative
for population-based screening for early detection of
colorectal cancer (CRC). The objective of this study was to
evaluate and validate plasma proteins individually and as a
signature for early detection of CRC.In a three-stage
design, proteins were measured firstly by liquid
chromatography/multiple reaction monitoring-mass
spectrometry (LC/MRM-MS) and later by proximity extension
assay (PEA) in a discovery set consisting of 96 newly
diagnosed CRC cases and 94 controls free of neoplasms at
screening colonoscopy. Two algorithms (one for each
measurement method) were derived by Lasso regression and
.632+ bootstrap based on 11 proteins that were included in
both the LC/MRM-MS and PEA measurements. Additionally,
another algorithm was constructed from the same eleven
biomarkers plus amphireglin, the most promising protein
marker in the PEA measurements that had not been available
from the LC/MRM-MS measurements. Lastly the three prediction
signatures were validated with PEA in independent samples of
participants of screening colonoscopy (CRC (n = 56),
advanced adenoma (n = 101), and participants free of
neoplasm (n = 102)).The same four proteins were included in
all three prediction signatures; mannan binding lectin
serine protease 1, osteopontin, serum paraoxonase lactonase
3 and transferrin receptor protein 1, and the third
prediction signature additionally included amphiregulin. In
the independent validation set from a true screening
setting, the five-marker blood-based signature including
AREG presented areas under the curves of 0.82 $(95\%$ CI,
0.74-0.89), 0.86 $(95\%$ CI, 0.77-0.92) and 0.76 $(95\%$ CI,
0.64-0.86) for all, early and late stages CRC,
respectively.Two different measurement methods consistently
identified four protein markers and an algorithm
additionally including amphiregulin, a marker measured by
PEA only, showed promising performance for detecting early
stage CRC in an independent validation in a true screening
setting. These proteins may be potential candidates for
blood-based tests for early detection of CRC.},
cin = {C120 / C070 / C060 / L101},
ddc = {610},
cid = {I:(DE-He78)C120-20160331 / I:(DE-He78)C070-20160331 /
I:(DE-He78)C060-20160331 / I:(DE-He78)L101-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:31557860},
doi = {10.3390/cancers11101426},
url = {https://inrepo02.dkfz.de/record/147183},
}